ติดตาม
David Yeung
David Yeung
Precision Medicine, SAHMRI, Adelaide
ยืนยันอีเมลแล้วที่ adelaide.edu.au
ชื่อ
อ้างโดย
อ้างโดย
ปี
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
DM Ross, S Branford, JF Seymour, AP Schwarer, C Arthur, DT Yeung, ...
Blood, The Journal of the American Society of Hematology 122 (4), 515-522, 2013
8672013
Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure
TP Hughes, MJ Mauro, JE Cortes, H Minami, D Rea, DJ DeAngelo, ...
New England Journal of Medicine 381 (24), 2315-2326, 2019
4042019
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
S Branford, DT Yeung, WT Parker, ND Roberts, L Purins, JA Braley, ...
Blood, The Journal of the American Society of Hematology 124 (4), 511-518, 2014
2362014
Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose …
AJC Bloor, A Patel, JE Griffin, MH Gilleece, R Radia, DT Yeung, D Drier, ...
Nature medicine 26 (11), 1720-1725, 2020
2332020
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
S Branford, DT Yeung, DM Ross, JA Prime, CR Field, HK Altamura, ...
Blood, The Journal of the American Society of Hematology 121 (19), 3818-3824, 2013
2292013
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
S Branford, P Wang, DT Yeung, D Thomson, A Purins, C Wadham, ...
Blood, The Journal of the American Society of Hematology 132 (9), 948-961, 2018
1932018
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
DT Yeung, MP Osborn, DL White, S Branford, J Braley, A Herschtal, ...
Blood, The Journal of the American Society of Hematology 125 (6), 915-923, 2015
1162015
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
DM Ross, IS Pagani, N Shanmuganathan, CH Kok, JF Seymour, AK Mills, ...
Leukemia 32 (12), 2572-2579, 2018
812018
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
WT Parker, DTO Yeung, AL Yeoman, HK Altamura, BA Jamison, CR Field, ...
Blood, The Journal of the American Society of Hematology 127 (15), 1870-1880, 2016
742016
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment
LN Eadie, P Dang, VA Saunders, DT Yeung, MP Osborn, AP Grigg, ...
Leukemia 31 (1), 75-82, 2017
712017
Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells
YD Irani, A Hughes, J Clarson, CH Kok, N Shanmuganathan, DL White, ...
British Journal of Haematology 191 (3), 433-441, 2020
682020
Consumer engagement in health care policy, research and services: A systematic review and meta-analysis of methods and effects
LK Wiles, D Kay, JA Luker, A Worley, J Austin, A Ball, A Bevan, M Cousins, ...
PloS one 17 (1), e0261808, 2022
652022
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia
N Shanmuganathan, IS Pagani, DM Ross, S Park, ASM Yong, JA Braley, ...
Blood, The Journal of the American Society of Hematology 137 (9), 1196-1207, 2021
652021
TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy
E Nievergall, J Reynolds, CH Kok, DB Watkins, M Biondo, SJ Busfield, ...
Leukemia 30 (6), 1263-1272, 2016
622016
High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment
SL Heatley, T Sadras, CH Kok, E Nievergall, K Quek, P Dang, B McClure, ...
Haematologica 102 (12), e490, 2017
602017
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
S Branford, DT Yeung, JA Prime, SY Choi, J Bang, JE Park, DW Kim, ...
Blood, The Journal of the American Society of Hematology 119 (18), 4264-4271, 2012
582012
Differential effects on gene transcription and hematopoietic differentiation correlate with GATA2 mutant disease phenotypes
CE Chong, P Venugopal, PH Stokes, YK Lee, PJ Brautigan, DTO Yeung, ...
Leukemia 32 (1), 194-202, 2018
572018
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
IS Pagani, P Dang, VA Saunders, R Grose, N Shanmuganathan, CH Kok, ...
Leukemia 34 (4), 1052-1061, 2020
452020
KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease
MO Forgione, BJ McClure, LN Eadie, DT Yeung, DL White
Cancer letters 469, 410-418, 2020
432020
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia
S Kimura, L Montefiori, I Iacobucci, Y Zhao, Q Gao, EM Paietta, ...
Blood, The Journal of the American Society of Hematology 139 (24), 3519-3531, 2022
402022
ระบบไม่สามารถดำเนินการได้ในขณะนี้ โปรดลองใหม่อีกครั้งในภายหลัง
บทความ 1–20